Back

Comprehensive Invitro and Insilico Analysis of Secondary Metabolites from Datura metel: Promising Anti-Alzheimer's Therapeutics.

Sharma, M.; Jain, M.; Patil, N.; Barnwal, A.; Tayade, S.; Delta, A. K.; Kole, C.; Kaushik, P.

2024-03-26 neuroscience
10.1101/2024.03.21.586063 bioRxiv
Show abstract

This research investigates secondary metabolites from Datura metel as potential anti-Alzheimers therapies. In vitro techniques isolated extracts for AD pathology targeting, with in silico analysis identifying gene targets for prevention. Apigenin, Luteolin, and Withanolide A were studied, each with 300 potential gene targets and core gene counts of 54, 52, and 58 respectively. Lipinskis Rule assessed their pharmacological properties, showing good absorption but limited blood-brain barrier penetration. Protein interaction mapping revealed shared targets among the compounds. GO enrichment and KEGG pathway analysis highlighted their impact on biological processes and pathways, suggesting their anti-Alzheimers potential. Luteolin notably reduced A{beta}1-42 levels by up to 35.2% (*p<0.05) in SH-SY5Y cells, positioning it and Withanolide A as promising multi-functional Alzheimers medications. These findings underscore the significance of Datura phytochemicals in AD prevention and treatment.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.